Clinical trials
CMV clinical trials
Below are recruiting cmv clinical trials, each written for real people, not researchers. We’re tracking 55 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06694428Recruiting
Testing a software tool for CMV blood test results in pregnancy
This trial is testing a computer program that helps doctors interpret blood test results for CMV infection in pregnant women. If you are pregnant and have had a CMV blood test, this study may help doctors better understand your results.
LimogesAges 18 years+ - NCT06555432Recruiting
Study of maribavir for CMV infection after transplant
This study tests a medication called LIVTENCITY (maribavir) for adults in South Korea who have a CMV infection after a transplant. It is for people whose infection has not improved or has become resistant to other antiviral medicines.
SeoulAges 19 years+ - NCT06243731Recruiting
Maribavir for CMV after transplant in kidney failure
This study looks at how well the drug maribavir works in adults with kidney failure who get a CMV infection after a transplant. It focuses on people whose CMV infection hasn't responded to other treatments.
Anderlecht, Brussels CapitalAges 18 years+ - NCT05708755RecruitingPhase 2
Monitoring immune response to CMV after lung transplant
This Phase 2 study monitors how your immune system reacts to CMV (a common virus) after a lung transplant. It may help doctors understand which patients are better protected and could guide future treatments to reduce CMV-related complications.
New York, New YorkAges 18–99 - NCT05319353RecruitingPhase 3
Maribavir for kids with CMV after transplant
This Phase 3 trial tests maribavir (an anti-CMV medicine) in children and teens who get CMV infection after a stem cell or solid organ transplant. It aims to see whether the drug is safe and well-tolerated, and whether it can reduce the virus in the body.
Wilmington, DelawareAges Up to 17 years - NCT03665675RecruitingEarly Phase 1
Immune cell treatment to control CMV or adenovirus after transplant
This early-phase study tests donor immune cells made to recognize CMV (a virus) or adenovirus, given to help control virus reactivation after a solid organ or bone marrow transplant. It may help reduce ongoing or worsening viral infection when standard antiviral medicines are hard to tolerate or not working well.
Columbus, OhioAges 1–85 - NCT03354728RecruitingPhase 1/Phase 2
Vaccine trial for children with CMV after stem cell transplant
This trial studies a vaccine designed to help the body fight cytomegalovirus (CMV) in children who test positive for CMV and are about to receive a donor stem cell transplant. If it works, it may reduce CMV-related illness during recovery after transplant.
Duarte, CaliforniaAges 1–21 - NCT07688759Recruiting
Immune response measurement for first CMV after transplant
This trial is for adults who have had a stem cell transplant and now have their first CMV infection. It tests a way to measure your immune response to CMV, which may help doctors decide the best treatment for you.
Suzhou, JiangsuAges 18 years+ - NCT07685457Recruiting
Virus-specific T cells for stubborn viral infections after transplant
This trial tests whether specially trained immune cells (virus-specific T cells) can safely treat stubborn viral infections after a stem cell transplant. It focuses on children and young adults who have not responded to standard antiviral treatments.
SeoulAges 1–25 - NCT07609576Recruiting
Tracking Infections in Blood Cancer Patients on Bispecific Antibody Treatment
This study follows adults with blood cancers (like multiple myeloma or lymphoma) who are starting a newer type of immunotherapy called bispecific antibodies. Researchers want to understand what infections might develop during this treatment and how often they occur, which could help doctors better protect patients.
Madrid, MadridAges 18 years+ - NCT07393594Enrolling by invitation
Tracer study for kidney transplant monitoring
This study looks at a new blood test to help monitor the health of your transplanted kidney and check for early signs of rejection. The test will be done as part of your usual care after a kidney transplant.
Phoenix, ArizonaAges 18 years+ - NCT07294547Recruiting
Comparing two antivirals for kidney transplant patients
This trial compares two antiviral drugs, valacyclovir and valganciclovir, to see if valacyclovir works as well as valganciclovir for preventing CMV and EBV infections after a kidney transplant.
TaipeiAges 3 years+ - NCT07235683RecruitingPhase 4
Stronger CMV treatment for lung transplant recipients
This trial tests adding a drug called letermovir to standard antiviral therapy for lung transplant patients with CMV infection. The goal is to see if the combination helps clear the virus faster and more effectively.
Toronto, OntarioAges 18 years+ - NCT04030676Recruiting
Test for CMV reactivation risk during ulcerative colitis flare
This study checks whether a blood test (QuantiFERON-CMV, related to prior CMV infection) can predict if CMV might reactivate during a severe ulcerative colitis flare. It may help doctors spot people at higher risk and potentially guide monitoring and treatment during hospitalization.
LyonAges 18 years+ - NCT07096453RecruitingPhase 1/Phase 2
CMV prevention in kidney transplant patients switching to belatacept
This trial tests whether an experimental drug (CMVIG) can prevent CMV infection in kidney transplant patients who are switching to or already on belatacept, a newer immunosuppressant. It may help protect those at higher risk for CMV.
Minneapolis, MinnesotaAges 18–70 - NCT07013370Recruiting
Preventing CMV in Children After Stem Cell Transplant
This trial tests whether a special antibody treatment (CMV-specific immunoglobulin) can prevent CMV infections in children who have had a stem cell transplant from a donor. It may help protect your child’s immune system during recovery.
TriesteAges 1 month–18 years - NCT06958796RecruitingPhase 4
CMV immunoglobulin to prevent disease after transplant
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
Boston, MassachusettsAges 18–75 - NCT06853184RecruitingPhase 2
Artesunate for CMV in transplant patients
This trial tests a study drug called artesunate as a possible new treatment for CMV (a common virus) in people who have had a kidney, lung, heart, or liver transplant. It is for patients whose CMV infection requires treatment with standard antivirals like ganciclovir or valganciclovir.
Boston, MassachusettsAges 18 years+ - NCT06793124Recruiting
Comparing tests for CMV in bowel disease patients
This trial compares different diagnostic tests to find the best way to detect cytomegalovirus (CMV) organ disease in people with inflammatory bowel disease (IBD) whose symptoms get worse and need hospital care. The goal is to improve diagnosis and treatment for this complication.
Bologna, BolognaAges 18 years+ - NCT03266640RecruitingPhase 2
CMV cell therapy for difficult-to-treat viral infection
This trial tests an immune cell treatment (CMV-specific cytotoxic T cells) for people with a CMV infection that is not improving despite standard antivirals, or who cannot tolerate them. If eligible, the treatment aims to help the body control the virus after transplant-related immune problems.
Los Angeles, CaliforniaAges 1 month–79 years - NCT06577363Recruiting
Maribavir tablets for CMV infection after transplant
This study looks at the medication maribavir for people who have a CMV infection after a transplant that is not getting better with current treatments. The goal is to see how well maribavir works in this situation.
Tokyo, TokyoAges Any age - NCT06575374RecruitingPhase 2
Letermovir to prevent CMV after CAR T-cell therapy
This trial tests if a drug called letermovir can safely prevent CMV (a common virus) from reactivating after you receive CAR T-cell therapy (Axi-cel). It may help reduce infections and side effects.
Houston, TexasAges 18 years+ - NCT06407232RecruitingPhase 3
Letermovir for CMV after kidney or pancreas transplant
This trial tests whether a drug called letermovir can safely treat CMV infection in people who have had a kidney or pancreas transplant. It is for those who are at high risk for CMV and whose own immune system cannot fight the virus.
Madison, WisconsinAges 18 years+ - NCT06252402RecruitingEarly Phase 1
CAR T cells for HIV: A new immunotherapy study
This trial tests a new type of immune cell, called a CAR T cell, that is designed to target and kill cells infected with HIV. It may help control the virus without needing to take HIV medication all the time.
Duarte, CaliforniaAges 18 years+
Hear when a new CMV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cmv?
- Yes. Clin2 currently lists 55 recruiting cmv studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cmv trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cmv trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.